Management of wheeze and cough in infants and pre-schoo ehildren in primary car

Paul Stephenso

Paul Stephenso

fGP, PCRJ News Edito

Correspondence to

Dr. Paul Stephenso

Christmas Malting

Tel: + 44 (0)1440 702203

gstephen@gpiag-asthma.or

Haverhill Suffol

Prim Care Resp

2002;11()442-4

\$urger

Introductio

Management of wheeze and cough in children is common problem in primary care. In this paper I ai to provide a few useful management tools with regar to diagnosis, the role of a trial of treatment, and th rationale for referral. For an in-depth review see th article in this journal two years ago by Bush¹

Presentation of Symptom

Jt is always worth asking parents what they mean b the term 'wheeze' or 'cough'. The high-pitche musical noise of a wheeze usually on expiratio should not be confused with the sound of inspirator stridor. The sound of airflow through secretions i different again, and parents may describe their chil 'gomiting' when, in fact, the child has been coughin severely and bringing up phlegm or mucus.

An acute presentation requires immediate referral t hospital if appropriate. Probably the commonest caus in the infant is bronchiolitis, and in the pre-schoo shild, viral induced wheeze or croup. Unilateral sign eould represent an inhaled foreign body, and a febril child with tachypnoea may well have a pneumonia Pertussis may have to be considered, particularly i fhere is a relevant non-immunisation history. I immediate transfer to hospital is not required, fo example after nebulisation, it is of course essential t review the situation closely and give parents clea instructions regarding review

With a prolonged history, the pattern of symptoms wil often give the clue to the underlying diagnosis (Figur 1). Episodic symptoms occurring solely with a vira infection should be differentiated from intercurrent o chronic symptoms which may occur at night and afte gxercise, perhaps in the context of a personal or famil history of atopy.

The concept of 'cough variant asthma' (asthm presenting solely as cough in the absence of wheeze is well established in adults² shough there remain some controversy about its diagnosis in children eve kince Spelman's uncontrolled study of children wit nhronic cough successfully treated according to a asthma protocol³ Without the ability to perform lun function tests in pre-school children, care must b taken to exclude other diagnoses. A persisten **productiv** cough may be due solely to chroni eatarrh with postnasal drip, but early referral may b needed. A persistent **dry** oough, worse at night and o sxercise, and without evidence of other diagnose warrants a trial of asthma treatment

The younger the child, the longer the list o differential diagnoses and the more one has t eonsider possibilities other than 'asthma'. Thes Include upper airways disease, congenital structura disease of the bronchi, bronchial or trachea compression by cardiac enlargement o -lymphadenopathy, foreign body or tumour, gastro besophageal reflux, laryngeal problems, causes o plersistent productive cough such as cystic fibrosis an primary ciliary dyskinesia as well as immuno deficiency and miscellaneous causes such a bronchopulmonary dysplasia and pulmonary oedema¹

Longitudinal Studies and Wheezing Phenotype

Our understanding of the natural history of wheez (and cough) has increased considerably over the las ten years. The British National Cohort Stud⁴ reported on 880 children given a label of asthma o wheezy bronchitis before the age of 7; two third trew out of symptoms by their late teens and a smal number of these had a recurrence of their symptoms i mid adult life. The data from Tucson, Arizon⁵, **k**a provided us with more detailed data in the early year of life. 862 children have been followed up for ove fourteen years. Using objective measurements such a IgE level, methacholine response, skin prick testing and prospective assessment of the presence of wheeze Martinez *et al* confirmed that there are several

Figure 1. Patterns of wheeze in young children (reproduced with kind permission of Professor M Silverman⁹



Personal Opinio

different wheezing phenotypes

- Transient early wheezers, 60% of whom are not wheezing by the age of 6, show a strong association with maternal smoking during pregnancy. They have reduced lung function at keast up to the age of 6, and their prevalence peak at around the age of 18 months to 2 years
- Non-atopic wheezers have no change in their IgE status, and their wheezing relates to viral-induce peak flow variability. Their prevalence peaks at about 4 years
- Persistent wheezers have raised IgE level at age 9 thonths and have methacholine responsiveness an peak flow variability. This group often have a significant family history of atopy particularly on the maternal side, have significantly reduced lung function at the age of 6 (presumably due to T-cell driven eosinophil-mediated chronic inflammation), and their prevalence graduall increases with the age of the cohort

These groups are not supposed to be exclusive nor ar they clear-cut, but the representation of these thre different wheezing phenotypes in terms of thei hypothetical yearly peak prevalence is extremel useful.

Evidence from other longitudinal studies (fo exampl ⁷) suggests that there may be a genetic basi for this phenotypical difference. Amongst children o thiddle-aged patients with previously diagnose asthma or 'wheezy bronchitis', the children of th hwheezy bronchitis' adults had reduced lung functio themselves, particularly in boys, at least raising th possibility of familial clusters of the 'wheez bronchitis' 'early wheezer' phenotype

Knowledge of these different wheezing phenotypes i pre-school children is a useful tool in the consultatio largely because of the implications for treatment Children presenting with persistent symptoms, with personal and/or family history of atopy, wit symptoms of wheeze and/or cough which are wors at night or on exercise, (the 'persistent wheezer phenotype), are likely to respond to anti-inflammator treatment. Similarly, children with the 'viral induce wheeze' phenotype, usually with no family o personal history of atopy and with no interva symptoms, are unlikely to have IgE-mediated atopi asthma, and are therefore unlikely to need regula treatment with inhaled steroids. Nevertheless, th situation is rarely this clear, since viral infections ar the commonest trigger for exacerbations of 'true persistent atopic asthma

f The Role of a Trial of Treatmen

A trial of treatment is therefore the next step (Figur 2). The rationale for a trial of treatment needs to b explained clearly to the child's parents. Th important point is that the treatment will be stoppe after three or four weeks, firstly to assess its succes and secondly to see whether symptoms recur, thereb helping to establish the diagnosis



The dose of inhaled steroids needs to be sufficientl high in order to control the inflammatory process i fhe airways quickly. Adult studies using a trial o treatment as a diagnostic too ² Have used inhale steroid dosages of 2000 mcg/day together with ora steroids if necessary. Therefore, one could use 200 400 mcg/day budesonide (or its equivalent) in th ander 2's and 400mcg/day in the 2 to 5 year olds vi metered dose inhaler, spacer and mask if needed Whether or not to use oral steroid (at a dose of mg/kg/day or less) will naturally depend on th severity of symptoms, and may depend upon th degree of parental anxiety, and the need fo 'something to be done now'

It is essential to have regular review during the tria of treatment and then a review as treatment ceases a **b**bout 4 weeks. Beaming smiles on the parents, wit hn asymptomatic child in tow, signify a successfu trial. Recurrence of symptoms needs further review and discussion about long-term low-dose inhaled anti inflammatory steroid treatment

When to Refe

If there has been no response to a good trial o streatment, with continuing parental anxiety, thi inevitably casts doubt on a diagnosis of 'asthma' and æferral is indicated. With only a partial respons there may still be residual parental anxiety and docto concern regarding dual pathology As children get older and become capable o performing reproducible peak flow measurements an spirometry, it is important to rethink the diagnosis i hater years if symptoms persist or recur. Inability t demonstrate variability with a beta-agonist challeng would cast some doubt on the diagnosis

The younger the child, the wider the differentia diagnosis, as discussed above, and the lower shoul by the threshold for referral to a respirator paediatrician

Einally, if the parents or GP are concerned about th ahild's progress in any way and things are 'not right', second opinion is always warranted.

Why bother to make the diagnosis and treat whe symptoms are mild

Children with a good response to a trial of treatmen and then recurrence of their symptoms warrant regula freatment with inhaled steroids. Give a dose o inhaled steroids sufficient to control the symptoms and then bring the dosage down to the minimum leve possible. The available inhaled steroids have differin dose-response curves, and in my opinion, budesonid is the initial treatment of choice in pre-schoo children. One may need to consider adding in seukotriene receptor antagonist (montelukast i lycensed from the age of two). When parents quer the role of long-term treatment, it is probably fair t mention the data from older children which show shat early treatment with inhaled steroids improve long-term lung function⁸ We are awaiting studies t see if these benefits can be extrapolated to the under 5's

Conclusio

In this paper, the first of our 'Personal Opinion' series hhave attempted to clarify aspects of history taking i Infants and pre-school children presenting with coug and wheeze, with particular emphasis on recen longitudinal studies showing the hypothetica prevalence of different wheezing phenotypes. Th younger the child, the more one should conside marities that require referral to a respirator paediatrician. A trial of treatment is a useful way o gstablishing the diagnosis and of differentiatin hetween those children who warrant long-ter inhaled steroids for atopic persistent asthma, an those who do not.

Acknowledgement

This paper is based on a workshop entitled 'Th Wheezy Infant' given as part of the Astra Zeneca ponsored FORUM (Future of Respiratory Medicine series. I gratefully acknowledge the input from D Dermot Ryan and Dr Vincent McGovern, both o whom have facilitated the workshop at differen Mines, as well as Dr John Haughney, the FORU Chairma

Reference :

t. Bush A. Diagnosis of asthma in children unde five. Asthma in Gen Pract 2000 8(1:4-6 T.McGarvey LPA, Heaney LG, Lawson J et al Evaluation and outcome of patients with chronic non productive cough using a comprehensive diagnosti protocol. Thorax 1998 5 :738-43 3. Spelman R. Two-year follow up of th management of chronic or recurring cough in childre according to an asthma protocol. Br J Gen Prac 1991 4 :406-409

4. Strachan D, Butland B, Anderson H, Nationa Cohort Study: incidence and prognosis of asthma an wheezing illness from early childhood to age 33 in national British cohort. BMJ 1996; 312: 1195-9 5. Martinez F D, Wright A L, Taussig L M et al Asthma and wheeze in the first six years of life. N Engl J Me 1995 33 :133-8

b. Stein R T, Holberg C J, Morgan W *bt a* k Pea dlow variability, methacholine responsiveness an gtopy as markers for detecting different wheezin phenotypes in childhood. Thorax 1997 2 :946-952 7. Christie G L, Helms P J, Ross S J et al Outcom for children of parents with atopic asthma an transient childhood wheezy bronchitis. Thorax 1997 **5**:953-7

&n Agertoft L, Pederson S. Effects of long ter hreatment with an inhaled corticosteroid on growt and pulmonary function in asthmatic children. Res Med 1994; 8 :373-81

9. Silverman M, Ed. Childhood asthma and othe wheezing disorders. 1995. Chapman and Hal Medical, London

Xochrane Airways Group, International Symposium 200 **6** to 7 November 2003, The Royal College of Physicians, Londo

eA major international two day symposium concerning evidence of the efficacy of therapy and its application in routin practice, guideline and protocol formulation in areas of respiratory disease including Acute asthma, Chronic asthma, Chroni abstructive pulmonary disease, Bronchiectasis, Sleep apnoe

KOnline registration: www.cochrane-airways.ac.u